August 15, 2022

Daily Company News

Better Informed Today

BUSINESS NEWS

MYND Life Sciences Is A Life Sciences Company Focused On Improving Mental Health

MYND Life Sciences was founded in May of 2020 by Dr. Wilfred Jefferies, a decorated immunologist at the University of British Columbia...
Listen to this article

Below is our recent interview with Jordan Cleland, Chief operating officer at MYND Life Sciences:

Q: Could you provide our readers with a brief introduction to your company?

A: MYND Life Sciences was founded in May of 2020 by Dr. Wilfred Jefferies, a decorated immunologist at the University of British Columbia; and Dr. Lyle Oberg, a physician by training and a former Alberta Cabinet Minister in the departments of Finance, Family and Social Services, Infrastructure and Transportation and Advanced Education and Education. The company is confident that our science has determined the way in which various psilocybin and psilocin analogues act as a molecular switch to reverse the inflammatory processes that causes major depressive disorder, sepsis, and other diseases of inflammation like Alzheimer’s disease. We will commercialize our science by means of three pathways:

  1. A suite of diagnostic biomarkers that detect specific proteins in bodily fluids.
  2. A vaccine and immunotherpeutic
  3. A pharmaceutical innovation and drug to treat depression, sepsis, and other diseases of inflammation.

Q: Any highlights on your recent announcement?

A: Our recent announcement was for a $3 million injection of working capital structured as a convertible debenture. A strategic investor took $2.5 million of the debenture, and we gathered the other $500,000 of participants from most retail investors in our network. The whole process went smoothly and was concluded in just under a month. Our first raise of $2.5 was similarly smooth, which suggest that our science, our leadership team and our promise to make a true generational drug innovation the the treatment of a depression and related illnesses is resonating with various classes of investors.

Q: What can we expect from your company in the next 6 months? What are your plans?

A: Over the next 6 months we expect to:

a) be into our Phase 2 Clinical trials,
b) Have commercialized a suite of proprietary diagnostic biomarkers.
c) Be well into our third round of financing of $15-20 million.Q:

Q: What is the best thing about your company that people might not know about?

A: We think we have one of the most distinguished scientists serving as our co-founder and Chief Science Officer in Dr. Jefferies. He is the only Canadian in the National Academy of Inventors, has been published over 100 times in prestigious scientific journals and was the first ever hire by Dr. Michael Smith, Canada’s first Nobel prize laureate. And on the business side, our CEO Dr. Oberg is both a man of science as a medical doctor and business/finance, having great entrepreneurial experience in gene sequencing, private health care and legalized cannabis; after serving public as a Cabinet Minister in the Alberta government.